89bio (ETNB)
NASDAQ:ETNB
US Market

89bio (ETNB) Stock Price & Analysis

434 Followers

ETNB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.00 - $12.95
Previous Close$11.5
Volume437.48K
Average Volume (3M)885.16K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$193.34M
Total Debt (Recent Filing)$20.02M
Price to Earnings (P/E)-2.6
Beta0.89
Next EarningsMar 22, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-4.35
Shares Outstanding46,536,970
R-Squared0.03
Standard Deviation0.28
10 Day Avg. Volume862,205
30 Day Avg. Volume885,159
Price to Book (P/B)3.65
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-10.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside124.35% Upside
Rating ConsensusStrong Buy
Alpha0.00707
Number of Analyst Covering6


Financials

Annual

ETNB FAQ

What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $2.00 and its highest was $12.95 in the past 12 months.
    What is 89bio’s market cap?
    Currently, no data Available
    When is 89bio’s upcoming earnings report date?
    89bio’s upcoming earnings report date is Mar 22, 2023 which is in 53 days.
      How were 89bio’s earnings last quarter?
      89bio released its earnings results on Nov 10, 2022. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.798 by $0.228.
        Is 89bio overvalued?
        According to Wall Street analysts 89bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does 89bio pay dividends?
          89bio does not currently pay dividends.
          What is 89bio’s EPS estimate?
          89bio’s EPS estimate is -$0.69.
            How many shares outstanding does 89bio have?
            89bio has 46,536,970 shares outstanding.
              What happened to 89bio’s price movement after its last earnings report?
              89bio reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.798. Following the earnings report the stock price went up 17.958%.
                Which hedge fund is a major shareholder of 89bio?
                Among the largest hedge funds holding 89bio’s share is RA Capital Management. It holds 89bio’s shares valued at 45M.

                  ---

                  89bio Stock Smart Score

                  9
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  81.67%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -69.29%
                  Trailing 12-Months
                  Asset Growth
                  19.35%
                  Trailing 12-Months
                  The 89bio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  89bio

                  89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Lexicon Pharmaceuticals
                  Kodiak Sciences
                  Protagonist Therapeutics
                  Poseida Therapeutics
                  Arbutus Biopharma

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis